Nature Cancer

Article	Citations
Untangling the threads of immunotherapy research	589
Outcompeting neighbors for intestinal cancer initiation	388
Gut decisions in CAR T cell therapy	381
Alzheimer’s drug turns macrophages against cancer	349
PARP11 interfer(on)es with CAR T cell efficacy	346
Enhancing childhood cancer targetability	314
Shooting for multiplexed pathology with Orion	295
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	293
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	289
A macrophage-activated abscopal effect	257
Breaking frontiers with multidisciplinary cancer research	232
MALAT1 protects dormant tumor cells from immune elimination	222
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	199
An oncolytic circular RNA therapy	199
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	193
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	187
A low-coverage liquid biopsy for lung cancer	183
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	181
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	177
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	174
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	159
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	148
The cGAS–STING pathway and cancer	144
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	139
Considering molecular alterations as pan-cancer tissue-agnostic targets	129

Expanding the options for KRAS inhibition	126
The importance of being generous	125
Reflecting on the golden age of cancer research	119
DePICting T cell–APC crosstalk in cancer	116
Beating cancer one carbon at a time	115
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	113
Stress granules shape metabolic reprogramming and drug resistance	113
Bone marrow progenitor-like cells against leukemia cure	112
Palmitate oxidation drives a pro-metastatic post-translational modification	111
Advancing therapeutics in small-cell lung cancer	108
Determinants of resistance and response to melanoma therapy	106
Shaping the microenvironment in peritoneal metastases	106
Impact of context-dependent autophagy states on tumor progression	106
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	106
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	100
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	97
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	97
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	94
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	94
Engineering-enhanced CAR T cells for improved cancer therapy	93
The labors of referees	92
LAG-3 and PD-1 blockade raises the bar for melanoma	91
Cycling back to folate metabolism in cancer	90
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	90
Thriving in diverse ecosystems	90
A quick guide for clinical oncology	86
Inflammation meets translation in AML	84
Antibody avidity meets multiple myeloma	83
Sarcoma ecotypes determine immunotherapy benefit	83
A comeback for checkpoint inhibition in multiple myeloma	83
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	81
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	81
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	81
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	80
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	80
Innate immunity drives epithelial cell plasticity during prostate tumor formation	80
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	80
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	79
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	79
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	78
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	78
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	77
Radioligand cancer therapy comes to the fore	76
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	76
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	76
Building a translational cancer dependency map for The Cancer Genome Atlas	75
Bispecific antibodies seek out colon cancer stem cells	75
Radiation sparks a dark side in neutrophils	75
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	75
How AI agents will change cancer research and oncology	75

CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	74
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	72
Dual inhibition of EGFR and PI3K with a single drug	72
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	72
Multimodal data integration improves immunotherapy response prediction	71
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	70
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	70
Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy	69
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	69
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	68
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	65
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	64
Immunotargeting of a recurrent AML-specific neoantigen	64
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	63
GEMys homing in on metastasis	62
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	62
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	61
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	60
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	60
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	59
Targeting BRCA-mutated tumors in mitosis	58
Selective targeting of malignant T cells	57
AKTing on XPO1 inhibition in AML	57
Highlights from the 2025 ASCO Annual Meeting	56
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	55
Bispecific chimeric T cell receptors tackle tumor heterogeneity	55
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	55
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	54
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	54
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	54
Advances in antibody-based therapy in oncology	53
The tumor microenvironment’s role in the response to immune checkpoint blockade	53
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	53
Epigenetic plasticity in PDAC	52
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	52
Anything to declare?	52
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	51
There are gremlins in prostate cancer	51
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	51
From the editor’s desk	51
Myeloma evades T cell-engaging therapies	51
Neoadjuvant immunotherapy marks a new era in oncology	51
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	50
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	50
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	50
In vivo macrophage engineering for renal cancer therapy	50
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	49
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	49
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	49
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	49
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	48
An unexpected career in cancer metabolism	48
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	46
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	45
Metabolic symbiosis in pancreatic cancer	45
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	45
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	45
Ricolinostat is not a highly selective HDAC6 inhibitor	44
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	43
A new sophistication for breast cancer PDXs	43
p53 at the crossroads of tumor immunity	43
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	43
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	43
Clinical and translational attributes of immune-related adverse events	43
Circumventing the roadblocks to targeting EGFR-driven cancers	43
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	42
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	42
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	42
Masking T cell engagers mitigates on-target off-tumor activity	42
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	41
Breaking the performance ceiling for neoantigen immunogenicity prediction	40
Understanding the biology of lung cancer brain metastases	40
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	40
CD8+ T cell killing of MHC class I–deficient tumors	39
CAR T cell therapy: looking back and looking forward	39
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	39
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	39
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	39
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	39
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	39

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	38
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	38
Communicating with respect	37
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	37
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	37
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	37
The meaning of impact	37
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	37
Leveraging translational insights toward precision medicine approaches for brain metastases	36
Harnessing the microbiome to restore immunotherapy response	36
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	36
Near-infrared optogenetic engineering of bacteria for cancer therapy	36
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	35
CD4+ CAR T cells — more than helpers	35
Leveraging the potential for deintensification in cancer care	34
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	34
Acute lymphoblastic leukemia displays a distinct highly methylated genome	34
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	34
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	33
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	33
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	33
Commensal metabolite boosts chemotherapy	33
Disparities, aging and childhood cancer	32
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	32
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	32
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	31
Immunoradiotherapy goes club(bing)	31
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	31
The aging lung reawakens dormant tumor cells	31
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
Targeting HIF-1 to treat AML	30
Fibrotic tumors tune metabolism for immune evasion	30
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	29
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	28
The landscape of T cell antigens for cancer immunotherapy	28
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	28
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	28
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	28
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	28
Probing clonal dynamics with single-cell genomics	27
Checkpoint blockade regulates T cell fate by supporting co-stimulation	27
CAR T cell therapy for multiple myeloma	27
The growing threat of cyberwarfare in cancer healthcare	27